Article Versions Notes

Barda B, Di Mari B, Soldini E, Di Bartolomeo C, Bissig M, Baserga A, Robatto A, Magenta L, Forlenza R, Cerny A. Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial. Scientia Pharmaceutica. 2024; 92(4):56. https://doi.org/10.3390/scipharm92040056

Barda, Beatrice, Bruno Di Mari, Emiliano Soldini, Claudia Di Bartolomeo, Maurizia Bissig, Adriana Baserga, Antonella Robatto, Lorenzo Magenta, Rossella Forlenza, and Andreas Cerny. 2024. "Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial" Scientia Pharmaceutica 92, no. 4: 56. https://doi.org/10.3390/scipharm92040056

Barda, B., Di Mari, B., Soldini, E., Di Bartolomeo, C., Bissig, M., Baserga, A., Robatto, A., Magenta, L., Forlenza, R., & Cerny, A. (2024). Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial. Scientia Pharmaceutica, 92(4), 56. https://doi.org/10.3390/scipharm92040056